Innateimmunity

Innate Cancer immunology

Cancer immunology is a dynamic and rapidly advancing branch of immunology that explores the complex interactions between the immune system and cancer cells (also referred to as tumors or malignancies). This field is at the forefront of biomedical research, with the primary goal of developing innovative immunotherapeutic strategies to prevent, treat, and slow the progression of cancer.

A central focus in cancer immunology is the immune system’s ability to recognize and respond to cancer-specific antigens. This understanding has fuelled the development of targeted therapies, including cancer vaccines, monoclonal antibodies, immune checkpoint inhibitors, and T-cell-based treatments, many of which have already transformed cancer care and continue to evolve through next-generation technologies.

In addition to therapeutic advances, the identification of tumor-associated antigens and immune biomarkers is leading to more precise diagnostic tools and personalized treatment approaches. A key discovery in this area was published by Ohtani in 2007, demonstrating the prognostic value of tumor-infiltrating lymphocytes (TILs) in human colorectal cancer. The presence of lymphocytic infiltration, particularly those triggering inflammatory responses, was associated with improved patient survival, suggesting that an endogenous anti-tumor immune response plays a meaningful role in disease outcomes.

By 2025, cancer immunology continues to push boundaries leveraging advancements in genomics, artificial intelligence, and cellular engineering to refine immunotherapies, overcome tumor immune evasion, and ultimately improve survival rates across a wide range of malignancies. The integration of cancer immunology into precision medicine frameworks marks a transformative era in oncology, offering renewed hope for effective, long-term cancer control.